- Home
- / BeiGene
BeiGene
Stock Price
$216.5
2024-10-29
Market Capitalization
$23.8 B
2024-10-29
Revenue
$3.8 B
FY, 2024
BeiGene Summary
Company Summary
- Overview
- BeiGene is a biotechnology company that discovers and develops oncology treatments. It focuses on targeted and immuno-oncology drugs that address unmet medical needs in a variety of cancer indications. Its products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.beigene.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Xiaodong Wang, Co-Founder, Chairman of Scientific Advisory Board
Xiaobin Wu, President, Chief Operating Officer & General Manager of China
Anita Wu, Chief Commercial Officer, Greater China
Operating MetricsView all
Patents Pending
21
FY, 2016
Patents Issued
8
FY, 2016
Registration Phase Products (Oncology)
25
3.8%
FY, 2020
LocationsView all
19 locations detected
Cambridge, MA HQ
United States
55 Cambridge Pkwy #700W
Emeryville, CA
United States
1900 Powell St #820
Fulton, MD
United States
8170 Maple Lawn Blvd #160
Ridgefield Park, NJ
United States
55 Challenger Rd #501Ridgefield
San Mateo, CA
United States
1840 Gateway Dr 3rd Floor
Buenos Aires, Cdad. Autónoma de Buenos Aires
Argentina
Arismendi 2441/43
BeiGene Financials
Summary Financials
- Revenue (FY, 2024)
- $3.8B
- Gross profit (FY, 2024)
- $3.2B
- Net income (FY, 2024)
- ($644.8M)
- Cash (FY, 2024)
- $2.6B
- EBIT (FY, 2024)
- ($568.2M)
- Enterprise value
- $23.3B